Friday, May 1, 2026

Kim Yong Chol Makes a Comeback in North Korean Media as Trump’s Second Term Approaches

Kim Yong Chol reemerges in North Korean media as Trump’s second term approaches, but his role in future negotiations remains uncertain.

The Void Whip: Kim Forces Slave Laborers To Build Him A Giant Sports Arena

North Korea commemorates Kim Jong Un's Mount Paektu march, emphasizing revolutionary traditions and local economic development efforts.

Kim Unveils “Hwasong-20” ICBM as China and Russia’s Top Officials Attend North Korea’s Anniversary Parade

Kim Jong Un showcased the new Hwasong-20 ICBM at the Workers' Party anniversary, emphasizing North Korea's nuclear status and alliances.

Tag: Celltrion

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Celltrion’s Eydenzelt: How Strategic Patent Agreements Enable U.S. and European Market Entry in 2026

Celltrion's Eydenzelt secures global distribution via strategic patent agreements, aiming for swift market entry in the U.S. and Europe.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.